Solid Tumour Group

Currently Recruiting


A Phase 1/2a Dose Escalation and Cohort Expansion Study for Safety, Tolerability, and Efficacy of BMS-986156 Administered Alone
and in Combination With Nivolumab (BMS-936558, Anti PD-1 Monoclonal Antibody) in Advanced Solid Tumours

Sponsor: Bristol-Myers Squibb

The purpose of this study is to evaluate the safety, tolerability pharmacokinetics, pharmacodynamics, immunogenicity and preliminary
 anti-tumor activity of BMS-986156 when administered alone and in combination with nivolumab in subjects with advanced solid tumours

More info: Click Here
Status: Recruiting
Contact: Jo Jackson


A Phase I/II, Open Label, Multicenter Study of the Safety and Efficacy of LAG525 Single Agent and in Combination
With PDR001 Administered to Patients With Advanced Malignancies

Sponsor: Novartis Pharmaceuticals

This study is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and anti-tumor activity of LAG525
as a single agent and in combination with PDR001 to adult patients with solid tumors. The study consists of a dose escalation phase (Ib) to
determine the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) for LAG525 as a single agent and in combination with PDR001,
and a dose expansion phase (II) which will characterize treatment of LAG525 as a single agent and in combination with PDR001 at the MTD or RP2D.

More info: Click Here
Status: Recruiting
Contact: Andrea Forero


A Phase 1A/1B, Open-Label, Multiple-Dose, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Preliminary Antitumor
Activities of the  BRAF Inhibitor BGB 283 in Subjects With Solid Tumors

Sponsor: BeiGene

This study will evaluate the safety, tolerability, pharmacokinetic profile and treatment effect of a new drug known as BGB-283 in patients with solid tumours.

More info: Click Here
Status: Recruiting
Contact: Rebecca Hinshelwood